Jim Lloyd

Identifying parkinsonism in mild cognitive impairment

Rishira Fernando, Alan Thomas, Calum A. Hamilton, Rory Durcan et autres

INTRODUCTION: Clinical parkinsonism is a core diagnostic feature for mild cognitive impairment with Lewy bodies (MCI-LB) but can be challenging to identify. A five-item scale derived from the Unified Parkinson's Disease Rating Scale (UPDRS) has been recommended for the assessment of parkinsonism …

gb (code pays fourni par la source)

Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls

Rory Durcan, Gemma Roberts, Calum A. Hamilton, Paul C. Donaghy et autres

BACKGROUND AND OBJECTIVES: Progressive nigrostriatal pathway degeneration occurs in individuals with dementia with Lewy bodies (LB). Our objective was to investigate whether repeat 123[I]-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) single photon emission computed tomography (SPECT) can identify progressive dopaminergic loss in mild cognitive impairment (MCI) …

gb, pt (code pays fourni par la source)

Clinical symptoms in mild cognitive impairment with Lewy bodies: Frequency, time of onset, and discriminant ability

Paul C. Donaghy, Calum A. Hamilton, Rory Durcan, Sarah Lawley et autres

BACKGROUND AND PURPOSE: Mild cognitive impairment with Lewy bodies (MCI-LB) is associated with a range of cognitive, motor, neuropsychiatric, sleep, autonomic, and visual symptoms. We investigated the cumulative frequency of symptoms in a longitudinal cohort of MCI-LB compared with MCI due to …

gb (code pays fourni par la source)

The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies

Paul C. Donaghy, Michael Firbank, George Petrides, Jim Lloyd et autres

INTRODUCTION: Amyloid-β (Aβ) deposition is common in dementia with Lewy bodies (DLB) and has been associated with more rapid disease progression. An effective biomarker that identified the presence of significant brain Aβ in people with DLB may be useful to identify and …

gb, se (code pays fourni par la source)

Can early phase cardiac [123I]mIBG images be used to diagnose Lewy body disease?

Gemma Roberts, Joseph Kane, Jim Lloyd, Michael Firbank et autres

PURPOSE: Some studies have suggested that cardiac [123I]metaiodobenzylguanidine images obtained 15-20 min after tracer administration are as accurate for dementia with Lewy bodies (DLB) diagnosis as standard images acquired after a delay of 3-4 h; some suggest delayed imaging is preferable. We …

gb, us, au (code pays fourni par la source)

Spatial covariance analysis of FDG-PET and HMPAO-SPECT for the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease

Matthew Ingram, Sean J. Colloby, Michael Firbank, Jim Lloyd et autres

gb (code pays fourni par la source)

Spatial covariance analysis of FDG-PET and HMPAO-SPECT for the differential diagnosis of dementia with Lewy bodies and Alzheimer’s disease

Matthew Ingram, Sean J. Colloby, Michael Firbank, Jim Lloyd et autres

Abstract We investigated diagnostic characteristics of spatial covariance analysis (SCA) of FDG-PET and HMPAO-SPECT scans in the differential diagnosis of dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD), in comparison with visual ratings and region of interest (ROI) analysis. Sixty-seven patients …

gb (code pays fourni par la source)

Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies

Gemma Roberts, Rory Durcan, Paul C. Donaghy, Sarah Lawley et autres

OBJECTIVE: To provide evidence that cardiac I-123-metaiodobenzylguanidine sympathetic innervation imaging (MIBG) scintigraphy differentiates probable mild cognitive impairment with Lewy bodies (MCI-LB) from mild cognitive impairment due to Alzheimer disease (MCI-AD), we scanned patients with MCI and obtained consensus clinical diagnoses of their …

gb, pt, us (code pays fourni par la source)

In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies

Julia Schumacher, John‐Paul Taylor, Calum A. Hamilton, Michael Firbank et autres

OBJECTIVES: To investigate in vivo degeneration of the cholinergic system in mild cognitive impairment with Lewy bodies (MCI-LB), we studied nucleus basalis of Meynert (NBM) volumes from structural MR images and its relation to EEG slowing and cognitive impairment. METHODS: We studied …

gb (code pays fourni par la source)

Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies

Gemma Roberts, Paul C. Donaghy, Jim Lloyd, Rory Durcan et autres

BACKGROUND: Dopaminergic imaging is an established biomarker for dementia with Lewy bodies, but its diagnostic accuracy at the mild cognitive impairment (MCI) stage remains uncertain. AIMS: To provide robust prospective evidence of the diagnostic accuracy of dopaminergic imaging at the MCI stage …

gb (code pays fourni par la source)

Mild cognitive impairment with Lewy bodies: blood perfusion with arterial spin labelling

Michael Firbank, John T. O’Brien, Rory Durcan, Louise Allan et autres

OBJECTIVE: To use arterial spin labelling to investigate differences in perfusion in mild cognitive impairment with Lewy bodies (MCI-LB) compared to Alzheimer type MCI (MCI-AD) and healthy controls. METHODS: We obtained perfusion images on 32 MCI-LB, 30 MCI-AD and 28 healthy subjects …

gb (code pays fourni par la source)

Mild cognitive impairment with Lewy bodies: neuropsychiatric supportive symptoms and cognitive profile

Paul C. Donaghy, Joanna Ciafone, Rory Durcan, Calum A. Hamilton et autres

BACKGROUND: Recently published diagnostic criteria for mild cognitive impairment with Lewy bodies (MCI-LB) include five neuropsychiatric supportive features (non-visual hallucinations, systematised delusions, apathy, anxiety and depression). We have previously demonstrated that the presence of two or more of these symptoms differentiates MCI-LB …

gb (code pays fourni par la source)